EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece
Abstract
Authors
MA Loupas K Lioliou G Gourzoulidis Z Vostitsanou A Giannakopoulou G Kourlaba